RCKT - rocketpharma.com Enterprise Value

Rocket Corp (RCKT) - corporate logo

The market valuation dynamics for Rocket Pharmaceuticals (RCKT) stand at 10.00, which correlates with high demand for advanced treatments in specialized centers. Rocket Pharmaceuticals (RCKT) minimizes risks by developing a series of projects focused on therapies for rare pediatric pathologies. The creation of unique blood and heart medications ensures long-term dominance through patents and the lifelong efficacy of the therapies.

RCKT Rocket Corp: Enterprise Value in the range 11/23/2025 - 10/28/2026

Rocket Pharmaceuticals (RCKT) - metric breakdowns and financial figures

- price and consensus price forecast:
Stock Quotes Rocket Pharma|RCKT - Price Target Chart
- market capitalization data:
Market Capitalization Rocket Pharmaceuticals|RCKT - Real Price to Acquire Entire Company
- book capitalization data:
Book Price of a Share Rocket Pharmaceuticals|RCKT - Book Capitalization|Capitalization to Book Value Ratio rocketpharma.com|RCKT - Aggregate Company Assets
- debt and liquidity data:
Debt to Equity Ratio Rocket Pharmaceuticals|RCKT - Long-Term Debt to Capital|Short-Term Debt to Capital rocketpharma.com|RCKT - Company Debts|Debt to Net Assets Ratio Rocket Pharmaceuticals|RCKT - Company Long-Term Debt|Short-Term Debt Rocket Pharmaceuticals
Comprehensive company analysis:Rocket Pharma (RCKT)
Original product of Rocket Pharmaceuticals

Enterprise value combines market capitalization and net debt, allowing for a real-time assessment of the actual business buyout price beyond quarterly reporting. By analyzing the enterprise value fluctuations of Rocket Pharmaceuticals (RCKT), an investor can evaluate the fairness of the company's valuation as it prepares for the first commercial launch of its gene therapy and actively expands its production capacities.

Direct competitors

Tempus AI - Real Price to Acquire Entire Company|Qiagen Group - Total Company Value|Isis Pharmaceuticals (IONS) - Enterprise Value|RGEN - Real Price to Acquire Entire Company|aviditybiosciences.com (RNA) - Aggregate Business Value|Enterprise Value CRISPR Therapeutics (CRSP)|Business Value WGS|Total Company Value Ultragenyx Pharma RARE|Business Value Beam Tx (BEAM)|Enterprise Value SRPT (Sarepta Therapeutics, Inc.)|twistbioscience.com - Enterprise Value|Total Company Value 10x Genomics (TXG)|NTLA: Value Adjusted for Debt and Cash|Total Company Value STOK|BioLife (BLFS) - Total Enterprise Value|Enterprise Value WVE|Real Price to Acquire Entire Company MAZE|Total Company Value SION|Enterprise Value Prime Medicine Inc (PRME)|TSHA: Enterprise Value|QURE - Total Enterprise Value|Real Price to Acquire Entire Company MeiraGTx Holdings plc MGTX|regenxbio.com (RGNX) - Aggregate Business Value|Real Price to Acquire Entire Company Solid Biosciences SLDB|OCGN (Ocugen Inc) - Value Adjusted for Debt and Cash|Total Company Value Pacific Biosciences of California PACB|Full Business Value Benitec Corp|Design Therapeutics (DSGN) - Enterprise Value|Value Adjusted for Debt and Cash 4dmoleculartherapeutics.com (FDMT)|Enterprise Value LXEO (Lexeo Therapeutics, Inc.)|Korro Bio Inc. - Enterprise Value|Total Company Value Editas (EDIT)|SLN: Value Adjusted for Debt and Cash|PRQR (proqr.com) - Total Company Value|Codexis (CDXS) - Real Price to Acquire Entire Company|SGMO (Sangamo Therapeutics, Inc.) - Enterprise Value|Enterprise Value Nautilus Biotechnology Inc|Enterprise Value MGX (Metagenomi, Inc)|Real Price to Acquire Entire Company precisionbiosciences.com (DTIL)|GBIO: Enterprise Value|BOLD - Total Enterprise Value|Exicure Corp - Real Price to Acquire Entire Company|Imunon, Inc. (IMNN) - Enterprise Value|PHIO - Real Price to Acquire Entire Company|Mustang Bio (MBIO) - Aggregate Business Value|RNAZ: Enterprise Value|Company Buyout Price Bionano|Enterprise Value APDN (Applied DNA Sciences, Inc.)|Real Price to Acquire Entire Company bluebird bio Inc. (BLUE)|Enterprise Value IPA (ImmunoPrecise Antibodies Ltd.)|Omega Therapeutics Corp - Enterprise Value|OMIC - Total Company Value|RGLS: Total Company Value|Syros Pharmaceuticals, Inc. - Total Company Value|TBIO (Telesis Bio Inc.) - Company Buyout Price|TCON - Total Company Value|Value Adjusted for Debt and Cash Unity Biotechnology, Inc